Siegel RL, Miller KD, Sauer AG, et al., 2020, Colorectal Cancer Statistics, 2020. CA Cancer J Clin, 70:7–30. DOI: 10.3322/caac.21601.

Feng RM, Zong YN, Cao SM, et al., 2019, Current Cancer Situation in China: Good or Bad News from the 2018 Global Cancer Statistics? Cancer Commun, 39:22. DOI: 10.1186/s40880-019-0368-6.

Cokkinides V, Albano J, Samuels A, et al., 2005, American Cancer Society: Cancer Facts and Figures. Atlanta: American Cancer Society.

Rosemurgy AS, Serafini FM, 2000, New Directions in Systemic Therapy of Pancreatic Cancer. Cancer Control, 7:437–44. DOI: 10.1177/107327480000700506.

Kong W, Engel K, Wang J, 2004, (Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) Mammalian Nucleoside Transporters. Curr Drug Metab, 5:63–84. DOI: 10.2174/1389200043489162.

Voutsadakis IA, 2011, Molecular Predictors of Gemcitabine Response in Pancreatic Cancer. World J Gastrointest Oncol, 3:153. DOI: 10.4251/wjgo.v3.i11.153.

Nagourney RA, Flam M, Link J, et al., 2008, Carboplatin Plus Gemcitabine Repeating Doublet Therapy in Recurrent Breast Cancer. Clin Breast Cancer, 8:432–5. DOI: 10.3816/cbc.2008.n.052.

Mini E, Nobili S, Caciagli B, et al., 2006, Cellular Pharmacology of Gemcitabine. Ann Oncol, 17:v7–v12. DOI: 10.1093/annonc/mdj941.

Huang P, Chubb S, Hertel LW, et al., 1991, Action of 2’, 2’-difluorodeoxycytidine on DNA Synthesis. Cancer Res, 51:6110–7.

Jin SF, Fan ZK, Pan L, et al., 2017, Gemcitabine-based Combination Therapy Compared with Gemcitabine Alone for Advanced Pancreatic Cancer: A Meta-analysis of Nine Randomized Controlled Trials. Hepatobiliary Pancreat Dis Int, 16:236–44. DOI: 10.1016/s1499-3872(17)60022-5.

Stathopoulos GP, Androulakis N, Souglakos J, et al., 2008, Present Treatment and Future Expectations in Advanced Pancreatic Cancer. Anticancer Res, 28:1303–8.

Burris HR, Moore MJ, Andersen J, et al., 1997, Improvements in Survival and Clinical Benefit with Gemcitabine as First-line Therapy for Patients with Advanced Pancreas Cancer: A Randomized Trial. J Clin Oncol, 15:2403–13. DOI: 10.1200/jco.1997.15.6.2403.

Shukla SK, Purohit V, Mehla K, et al., 2017, MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell, 32:71–-87. e77. DOI: 10.1016/j.ccell.2017.06.004.

Dauer P, Nomura A, Saluja A, et al., 2017, Microenvironment in Determining Chemo-resistance in Pancreatic Cancer: Neighborhood Matters. Pancreatology, 17:7-12. DOI: 10.1016/j.pan.2016.12.010.

Chand S, O’Hayer K, Blanco FF, et al., 2016, The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms. Int J Biol Sci, 12:273. DOI: 10.7150/ijbs.14951.

He X, Wang J, Wei W, et al., 2016, Hypoxia Regulates ABCG2 Activity through the Activivation of ERK1/2/HIF-1a and Contributes to Chemoresistance in Pancreatic Cancer Cells. Cancer Biol Ther, 17:188–98. DOI: 10.1080/15384047.2016.1139228.

Nagaraju GP, Zakka KM, Landry JC, et al., 2019, Inhibition of HSP90 Overcomes Resistance to Chemotherapy and Radiotherapy in Pancreatic Cancer. Int J Cancer, 145:1529–37. DOI: 10.1002/ijc.32227.

Arora S, Bhardwaj A, Singh S, et al., 2013, An Undesired Effect of Chemotherapy Gemcitabine Promotes Pancreatic Cancer Cell Invasiveness through Reactive Oxygen Species-dependent, Nuclear Factor kB-and Hypoxia-inducible Factor 1a-mediated up-Regulation of CXCR4. J Biol Chem, 288:21197–207. DOI: 10.1158/1538-7445.am2013-4794.

Cheng ZX, Wang DW, Liu T, et al., 2014, Effects of the HIF-1a and NF-kB loop on Epithelialmesenchymal Transition and Chemoresistance Induced by Hypoxia in Pancreatic Cancer Cells. Oncol Rep, 31:1891–8. DOI: 10.3892/or.2014.3022.

Zhao T, Jin F, Di Xiao HW, et al., 2020, IL-37/STAT3/HIF-1a Negative Feedback Signaling Drives Gemcitabine Resistance in Pancreatic Cancer. Theranostics, 10:4088. DOI: 10.7150/thno.42416.

Luo G, Xia X, Wang X, et al., 2018, miR-301a Plays a Pivotal Role in Hypoxia-induced Gemcitabine Resistance in Pancreatic Cancer. Exp Cell Res, 369:120–8. DOI: 10.1016/j.yexcr.2018.05.013.

Yang Y, Tian W, Yang L, et al., 2020, Gemcitabine Potentiates Anti-tumor Effect of Resveratrol on Pancreatic Cancer Via Down-regulation of VEGF-B. J Cancer Res Clin Oncol, 147:93–103. DOI: 10.1007/s00432-020-03384-7.

Reddy LH, Khoury H, Paci A, et al., 2008, Squalenoylation Favorably Modifies the In Vivo Pharmacokinetics and Biodistribution of Gemcitabine in Mice. Drug Metab Dispos, 36:1570–7. DOI: 10.1124/dmd.108.020735.

Gandhi V, Plunkett W, 1990, Modulatory Activity of 2’, 2’-difluorodeoxycytidine on the Phosphorylation and Cytotoxicity of Arabinosyl Nucleosides. Cancer Res, 50:3675–80.

Hertel LW, Boder GB, Kroin JS, et al., 1990, Evaluation of the Antitumor Activity of Gemcitabine (2’, 2’-difluoro-2’-deoxycytidine). Cancer Res, 50:4417–22.

Mackey JR, Baldwin SA, Young JD, et al., 1998, Nucleoside Transport and its Significance for Anticancer Drug Resistance. Drug Resist Updates, 1:310–24. DOI: 10.1016/s1368-7646(98)80047-2.

Mackey JR, Mani RS, Selner M, et al., 1998, Functional Nucleoside Transporters are Required for Gemcitabine Influx and Manifestation of Toxicity in Cancer Cell Lines, Cancer Res, 58:4349–57.

Young JD, Yao SY, Baldwin JM, et al., 2013, The Human Concentrative and Equilibrative Nucleoside Transporter Families, SLC28 and SLC29. Mol Aspects Med, 34:529–47. DOI: 10.1016/j.mam.2012.05.007.

Ritzel M, Yao S, Huang M, et al., 1997, Molecular Cloning and Functional Expression of cDNAs Encoding a Human Na+-nucleoside Cotransporter (hCNT1). Am J Physiol Cell Physiol, 272:C707–14. DOI: 10.1152/ajpcell.1997.272.2.c707.

Smith KM, Slugoski MD, Loewen SK, et al., 2005, The Broadly Selective Human Na+/nucleoside Cotransporter (hCNT3) Exhibits Novel Cation-coupled Nucleoside Transport Characteristics. J Biol Chem, 280:25436–49. DOI: 10.1074/jbc.m409454200.

Gray JH, Owen RP, Giacomini KM, 2004, The Concentrative Nucleoside Transporter Family, SLC28. Pflügers Archiv, 447:728–34. DOI: 10.1007/s00424-003-1107-y.

Lostao MP, Mata JF, Larrayoz IM, et al., 2000, Electrogenic Uptake of Nucleosides and Nucleoside‐derived Drugs by the Human Nucleoside Transporter 1 (hCNT1) Expressed in Xenopus Laevis Oocytes. FEBS Lett, 481:137–40. DOI: 10.1016/s0014-5793(00)01983-9.

Barnes K, Dobrzynski H, Foppolo S, et al., 2006, Distribution and Functional Characterization of Equilibrative Nucleoside Transporter-4, a Novel Cardiac Adenosine Transporter Activated at Acidic pH. Circ Res, 99:510–9. DOI: 10.1161/01.res.0000238359.18495.42.

Baldwin SA, Yao SY, Hyde RJ, et al., 2005, Functional Characterization of Novel Human and Mouse Equilibrative Nucleoside Transporters (hENT3 and mENT3) Located in Intracellular Membranes. J Biol Chem, 280:15880–7. DOI: 10.1074/jbc.m414337200.

Hyde R, Abidi F, Griffiths M, et al., 2000, Probing the Structure/Function Relationships of Human Equilibrative Nucleoside Transporters Using Site-directed Mutagenesis. Drug Dev Res, 50:38. DOI: 10.1042/bst028a093b.

Govindarajan R, Leung GP, Zhou M, et al., 2009, Facilitated Mitochondrial Import of Antiviral and Anticancer Nucleoside Drugs by Human Equilibrative Nucleoside Transporter-3. Am J Physiol Gastrointest Liver Physiol, 296:G910–22. DOI: 10.1152/ajpgi.90672.2008.

Zhou M, Duan H, Engel K, et al., 2010, Adenosine Transport by Plasma Membrane Monoamine Transporter: Reinvestigation and Comparison with Organic Cations. Drug Metab Dispos. 38:1798–805. DOI: 10.1124/dmd.110.032987.

Damaraju VL, Mowles D, Yao S, et al., 2012, Role of Human Nucleoside Transporters in the Uptake and Cytotoxicity of Azacitidine and Decitabine. Nucleosides Nucleotides Nucleic Acids, 31:236–55. DOI: 10.1080/15257770.2011.652330.

de Sousa Cavalcante L, Monteiro G, 2014, Gemcitabine: Metabolism and Molecular Mechanisms of Action, Sensitivity and Chemoresistance in Pancreatic Cancer. Eur J Pharmacol, 741:8–16. DOI: 10.1016/j.ejphar.2014.07.041.

DeGorter M, Xia C, Yang J, et al., 2012, Drug Transporters in Drug Efficacy and Toxicity. Ann Rev Pharmacol Toxicol, 52:249–73. DOI: 10.1146/annurev-pharmtox-010611-134529.

Santini D, Schiavon G, Vincenzi B, et al., 2011, Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients with Biliary Tract Cancer (BTC). Curr Cancer Drug Targets, 11:123–9. DOI: 10.2174/156800911793743600.

Spratlin J, Sangha R, Glubrecht D, et al., 2004, The Absence of Human Equilibrative Nucleoside Transporter 1 is Associated with Reduced Survival in Patients with Gemcitabine-treated Pancreas Adenocarcinoma. Clin Cancer Res, 10:6956–61. DOI: 10.1158/1078-0432.ccr-04-0224.

Achiwa H, Oguri T, Sato S, et al., Determinants of Sensitivity and Resistance to Gemcitabine: The Roles of Human Equilibrative Nucleoside Transporter 1 and Deoxycytidine Kinase in Non‐Small Cell Lung Cancer. Cancer Sci, 95:753–57. DOI: 10.1111/j.1349-7006.2004.tb03257.x.

Maréchal R, Mackey JR, Lai R, et al., 2009, Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma. Clin Cancer Res, 15:2913–9. DOI: 10.1158/1078-0432.ccr-08-2080.

Giovannetti E, Del Tacca M, Mey V, et al., 2006, Transcription Analysis of Human Equilibrative Nucleoside Transporter-1 Predicts Survival in Pancreas Cancer Patients Treated with Gemcitabine. Cancer Res, 66:3928–35. DOI: 10.1158/0008-5472.can-05-4203.

Michalski C, Erkan M, Sauliunaite D, et al., 2008, Ex Vivo Chemosensitivity Testing and Gene Expression Profiling Predict Response towards Adjuvant Gemcitabine Treatment in Pancreatic Cancer. Br J Cancer, 99:760–7. DOI: 10.1038/sj.bjc.6604528.

Paproski RJ, Yao SY, Favis N, et al., 2013, Human Concentrative Nucleoside Transporter 3 Transfection with Ultrasound and Microbubbles in Nucleoside Transport Deficient HEK293 Cells Greatly Increases Gemcitabine Uptake. PLoS One, 8:e56423. DOI: 10.1371/journal.pone.0056423.

Galmarini C, Mackey J, Dumontet C, 2001, Nucleoside Analogues: Mechanisms of Drug Resistance and Reversal Strategies. Leukemia, 15:875–90. DOI: 10.1038/sj.leu.2402114.

Veltkamp SA, Beijnen JH, Schellens JH, 2008, Prolonged Versus Standard Gemcitabine Infusion: Translation of Molecular Pharmacology to New Treatment Strategy. Oncologist, 13:261–76. DOI: 10.1634/theoncologist.2007-0215.

Heinemann V, Xu YZ, Chubb S, et al., 1992, Cellular Elimination of 2’, 2’-Difluorodeoxycytidine 5’-triphosphate: A Mechanism of Self-potentiation. Cancer Res, 52:533–9.

Van Haperen VW, Veerman G, Boven E, et al., 1994, Schedule Dependence of Sensitivity to 2’, 2’-difluorodeoxycytidine (Gemcitabine) in Relation to Accumulation and Retention of its Triphosphate in Solid Tumour Cell Lines and Solid Tumours. Biochem Pharmacol, 48:1327–39. DOI: 10.1016/0006-2952(94)90554-1.

Plunkett W, Huang P, Gandhi V, 1995, Preclinical Characteristics of Gemcitabine. Anticancer Drugs, 6:7–13. DOI: 10.1097/00001813-199512006-00002.

Szekeres T, Fritzer-Szekeres M, Elford HL, et al., 1997, The Enzyme Ribonucleotide Reductase: Target for Antitumor and Anti-HIV Therapy. Crit Rev Clin Lab Sci, 34:503–28. DOI: 10.3109/10408369709006424.

Sarup JC, Johnson MA, Verhoef V, et al., 1989, Regulation of Purine Deoxynucleoside Phosphorylation by Deoxycytidine Kinase from Human Leukemic Blast Cells. Biochem Pharmacol, 38:2601–07. DOI: 10.1016/0006-2952(89)90544-3.

Habiro A, Tanno S, Koizumi K, et al., 2004, Involvement of p38 Mitogen-activated Protein Kinase in Gemcitabine-induced Apoptosis in Human Pancreatic Cancer Cells. Biochem Biophys Res Commun, 316:71–7. DOI: 10.1016/j.bbrc.2004.02.017.

Köpper F, Bierwirth C, Schön M, et al., 2013, Damage-induced DNA Replication Stalling Relies on MAPK-activated Protein Kinase 2 Activity. Proc Natl Acad Sci, 110:16856–61. DOI: 10.1073/pnas.1304355110.

Wang Z, Li Y, Ahmad A, et al., 2011, Pancreatic Cancer: Understanding and Overcoming Chemoresistance. Nat Rev Gastroenterol Hepatol, 8:27. DOI: 10.1038/nrgastro.2010.188.

Yoon H, Min JK, Lee JW, et al., 2011, Acquisition of Chemoresistance in Intrahepatic Cholangiocarcinoma Cells by Activation of AKT and Extracellular Signal-regulated Kinase (ERK) 1/2. Biochem Biophys Res Commun, 405:333–7. DOI: 10.1016/j.bbrc.2010.11.130.

Ng SS, Tsao MS, Chow S, et al., 2000, Inhibition of Phosphatidylinositide 3-kinase Enhances Gemcitabine-induced Apoptosis in Human Pancreatic Cancer Cells. Cancer Res, 60:5451–5.

Jin X, Pan Y, Wang L, et al., 2017, Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1–MAPK Interaction. Cancer Res, 77:4328–41. DOI: 10.1158/0008-5472.can-16-3143.

Mu GG, Zhang L, Li HY, et al., 2015, Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer. Dig Dis Sci, 60:1067–80. DOI: 10.1007/s10620-014-3394-x.

Akada M, Crnogorac-Jurcevic T, Lattimore S, et al., 2005, Intrinsic Chemoresistance to Gemcitabine is Associated with Decreased Expression of BNIP3 in Pancreatic Cancer. Clin Cancer Res, 11:3094–101. DOI: 10.1158/1078-0432.ccr-04-1785.

Giroux V, Iovanna J, Dagorn JC, 2006, Probing the Human Kinome for Kinases Involved in Pancreatic Cancer Cell Survival and Gemcitabine Resistance. FASEB J, 20:1982–91. DOI: 10.1096/fj.06-6239com.

Garraway LA, Jänne PA, 2012, Circumventing Cancer Drug Resistance in the Era of Personalized Medicine. Cancer Discov, 2:214-26. DOI: 10.1158/2159-8290.cd-12-0012.

Namba T, Kodama R, Moritomo S, et al., 2015, Zidovudine, an Anti-viral Drug, Resensitizes Gemcitabine-resistant Pancreatic Cancer Cells to Gemcitabine by Inhibition of the Akt-GSK3 b-Snail Pathway. Cell Death Dis, 6:e1795. DOI: 10.1038/cddis.2015.172.

Goggins M, Kern SE, Offerhaus J, et al., 1999, Progress in Cancer Genetics: Lessons from Pancreatic Cancer. Ann Oncol, 10:S4–8. DOI: 10.1093/annonc/10.suppl_4.s4.

Galmarini CM, Clarke ML, Falette N, et al., 2002, Expression of a Non-functional p53 Affects the Sensitivity of Cancer Cells to Gemcitabine. Int J Cancer, 97:439–45. DOI: 10.1002/ijc.1628.

Fiorini C, Cordani M, Padroni C, et al., 2015, Mutant p53 Stimulates Chemoresistance of Pancreatic Adenocarcinoma Cells to Gemcitabine. Biochim Biophys Acta, 1853:89–100. DOI: 10.1016/j.bbamcr.2014.10.003.

Lee JY, Song SY, Park JY, 2014, Notch Pathway Activation is Associated with Pancreatic Cancer Treatment Failure. Pancreatology, 14:48–53. DOI: 10.1016/j.pan.2013.11.011.

Wang Z, Li Y, Kong D, et al., 2009, Acquisition of Epithelial-mesenchymal Transition Phenotype of Gemcitabine-resistant Pancreatic Cancer Cells is Linked with Activation of the Notch Signaling Pathway. Cancer Res, 69:2400–7. DOI: 10.1158/0008-5472.can-08-4312.

Bao B, Wang Z, Ali S, et al., 2011, Notch-1 Induces Epithelial-mesenchymal Transition Consistent with Cancer Stem Cell Phenotype in Pancreatic Cancer Cells. Cancer Lett, 307:26–36. DOI: 10.1016/j.canlet.2011.03.012.

Xu M, He J, Li J, et al., 2017, Methyl-CpG-binding Domain 3 Inhibits Epithelial-Mesenchymal Transition in Pancreatic Cancer Cells Via TGF-b/Smad Signalling. Br J Cancer, 116:91–9. DOI: 10.1038/bjc.2016.397.

Wang J, Chen Y, Xiang F, et al., 2018, Suppression of TGF-b1 Enhances Chemosensitivity of Cisplatin-resistant Lung Cancer Cells through the Inhibition of Drug-resistant Proteins. Artif Cells Nanomed Biotechnol, 46:1505–12. DOI: 10.1080/21691401.2017.1374285.

Oshimori N, Oristian D, Fuchs E, 2015, TGF-b Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma. Cell, 160:963–76. DOI: 10.1016/j.cell.2015.01.043.

Jin X, Wu Y, 2014, Berbamine Enhances the Antineoplastic Activity of Gemcitabine in Pancreatic Cancer Cells by Activating Transforming Growth Factor-b/Smad Signaling. Anat Rec (Hoboken), 297:802–9. DOI: 10.1002/ar.22897.

Long J, Liu Z, Wu X, et al., 2016, siRNA-Mediated SBF2 Silencing May Inhibit Pancreatic Cancer Cells via Attenuation of the TGF-b Signaling Pathway. Technol Cancer Res Treatment, 15:308–13. DOI: 10.1177/1533034615580724.

Fischer T, Najjar A, Totzke F, et al., 2018, Discovery of Novel Dual Inhibitors of Receptor Tyrosine Kinases EGFR and PDGFR-b Related to Anticancer Drug Resistance. J Enzyme Inhib Med Chem, 33:1–8. DOI: 10.1080/14756366.2017.1370583.

Moore MJ, Goldstein D, Hamm J, et al., 2007, Erlotinib Plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 25:1960–6. DOI: 10.1200/jco.2006.07.9525.

Ricciardiello F, Gang Y, Palorini R, et al., 2020, Chiaradonna, Hexosamine Pathway Inhibition Overcomes Pancreatic Cancer Resistance to Gemcitabine through Unfolded Protein Response and EGFR-Akt Pathway Modulation. Oncogene, 39:4103–17. DOI: 10.1038/s41388-020-1260-1.

Chen R, Lai LA, Sullivan Y, et al., 2017, Disrupting Glutamine Metabolic Pathways to Sensitize Gemcitabine-resistant Pancreatic Cancer. Sci Rep, 7:7950. DOI: 10.1038/s41598-017-08436-6.

Mymrikov EV, Seit-Nebi AS, Gusev NB, 2011, Large Potentials of Small Heat Shock Proteins. Physiol Rev, 91:1123–59. DOI: 10.1152/physrev.00023.2010.

Hyun JJ, Lee HS, Keum B, et al., 2013, Expression of Heat Shock Protein 70 Modulates the Chemoresponsiveness of Pancreatic Cancer. Gut Liver, 7:739–46. DOI: 10.5009/gnl.2013.7.6.739.

Taba K, Kuramitsu Y, Ryozawa S, et al., 2011, KNK437 Downregulates Heat Shock Protein 27 of Pancreatic Cancer Cells and Enhances the Cytotoxic Effect of Gemcitabine. Chemotherapy, 57:12–6. DOI: 10.1159/000321019.

Suenaga S, Kuramitsu Y, Kaino S, et al., 2014, Active Hexose-correlated Compound Down-regulates HSP27 of Pancreatic Cancer Cells, and Helps the Cytotoxic Effect of Gemcitabine. Anticancer Res, 34:141–6. DOI: 10.1097/mpa.0b013e3181773970.

Cheng Y, Ma X, Wei Y, et al., 2019, Potential Roles and Targeted Therapy of the CXCLs/CXCR2 Axis in Cancer and Inflammatory Diseases. Biochim Biophys Acta, 1871:289–312. DOI: 10.1016/j.bbcan.2019.01.005.

Wang H, Ning Z, Li Y, et al., 2016, Bufalin Suppresses Cancer Stem-like Cells in Gemcitabine-resistant Pancreatic Cancer Cells Via Hedgehog Signaling. Mol Med Rep, 14:1907–14. DOI: 10.3892/mmr.2016.5471.

Onishi H, Katano M, 2011, Hedgehog Signaling Pathway as a Therapeutic Target in Various Types of Cancer. Cancer Sci, 102:1756–60. DOI: 10.1111/j.1349-7006.2011.02010.x.

Olive KP, Jacobetz MA, Davidson CJ, et al., 2009, Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer. Science, 324:1457–61. DOI: 10.1126/science.1171362.

De Jesus-Acosta A, Sugar EA, O’Dwyer PJ, et al., 2020, Phase 2 Study of Vismodegib, a Hedgehog Inhibitor, Combined with Gemcitabine and Nab-paclitaxel in Patients with Untreated Metastatic Pancreatic Adenocarcinoma. Br J Cancer, 122:498–505. DOI: 10.1038/s41416-019-0683-3.

Weizman N, Krelin Y, Shabtay-Orbach A, et al., 2014, Macrophages Mediate Gemcitabine Resistance of Pancreatic Adenocarcinoma by Upregulating Cytidine Deaminase. Oncogene, 33:3812–9. DOI: 10.1038/onc.2013.357.

Mitchem JB, Brennan DJ, Knolhoff BL, et al., 2013, Targeting Tumor-infiltrating Macrophages Decreases Tumor-initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses. Cancer Res, 73:1128–41. DOI: 10.1158/0008-5472.can-12-2731.

Ijichi H, Chytil A, Gorska AE, et al., 2011, Inhibiting Cxcr2 Disrupts Tumor-stromal Interactions and Improves Survival in a Mouse Model of Pancreatic Ductal Adenocarcinoma. J Clin Invest, 121:4106–17. DOI: 10.1172/jci42754.

Carbone C, Melisi D, 2012, NF-kB as a Target for Pancreatic Cancer Therapy. Expert Opin Ther Targets, 16:S1–10. DOI: 10.1517/14728222.2011.645806.

Saito K, Matsuo Y, Imafuji H, et al., 2018, Xanthohumol Inhibits Angiogenesis by Suppressing Nuclear Factor‐kB Activation in Pancreatic Cancer. Cancer Sci, 109:132–40. DOI: 10.1111/cas.13441.

Huang C, Huang R, Chang W, et al., The Expression and Clinical Significance of pSTAT3, VEGF and VEGF-C in Pancreatic Adenocarcinoma. Neoplasma, 59:52. DOI: 10.4149/neo_2012_007.

Huang C, Jiang T, Zhu L, et al., 2011, STAT3-targeting RNA Interference Inhibits Pancreatic Cancer Angiogenesis In Vitro and In Vivo. Int J Oncol, 38:1637–44. DOI: 10.3892/ijo.2011.1000.

Zhang Z, Duan Q, Zhao H, et al., 2016, Gemcitabine Treatment Promotes Pancreatic Cancer Stemness through the Nox/ROS/NF-kB/STAT3 Signaling Cascade. Cancer Lett, 382:53–63. DOI: 10.1016/j.canlet.2016.08.023.

Pan X, Arumugam T, Yamamoto T, et al., 2008, Nuclear Factor-kB p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells. Clin Cancer Res, 14:8143–51. DOI: 10.1158/1078-0432.ccr-08-1539.

Jing X, Yang F, Shao C, et al., 2019, Role of Hypoxia in Cancer Therapy by Regulating the Tumor Microenvironment. Mol Cancer, 18:157. DOI: 10.1186/s12943-019-1089-9.

Srivani G, Behera SK, Dariya B, et al., 2020, Resveratrol Binds and Inhibits Transcription Factor HIF-1a in Pancreatic Cancer. Exp Cell Res, 394:112126. DOI: 10.1016/j.yexcr.2020.112126.

Srivani G, Behera SK, Dariya B, et al., 2020, HIF-1a and RKIP: A Computational Approach for Pancreatic Cancer Therapy. Mol Cell Biochem, 472:95–103. DOI: 10.1007/s11010-020-03788-6.

Zimna A, Kurpisz M, 2015, Hypoxia-inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies. Biomed Res Int, 2015:549412. DOI: 10.1155/2015/549412.

Luo D, Wang Z, Wu J, et al., 2014, The Role of Hypoxia Inducible Factor-1 in Hepatocellular Carcinoma. Biomed Res Int, 2014:409272. DOI: 10.1155/2014/409272.

Karakashev SV, Reginato MJ, 2015, Progress toward Overcoming Hypoxia-induced Resistance to Solid Tumor Therapy. Cancer Manag Res, 7:253. DOI: 10.2147/cmar.s58285.

DeBerardinis RJ, Lum JJ, Hatzivassiliou G, et al., 2008, The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation. Cell Metab, 7:11–20. DOI: 10.1016/j.cmet.2007.10.002.

Semenza GL, 2012, Hypoxia-inducible Factors in Physiology and Medicine. Cell, 148:399–408. DOI: 10.1016/j.cell.2012.01.021.

Semenza GL, 2010, HIF-1: Upstream and Downstream of Cancer Metabolism. Curr Opin Genet Dev, 20:51–6. DOI: 10.1016/j.gde.2009.10.009.

Bartrons R, Caro J, 2007, Hypoxia, Glucose Metabolism and the Warburg’s Effect. J Bioenerg Biomembr, 39:223–9. DOI: 10.1007/s10863-007-9080-3.

Denko NC, 2008, Hypoxia, HIF1 and Glucose Metabolism in the Solid Tumour. Nat Rev Cancer, 8:705–13. DOI: 10.1038/nrc2468.

McGuigan A, Kelly P, Turkington RC, et al., 2018, Pancreatic Cancer: A Review of Clinical Diagnosis, Epidemiology, Treatment and Outcomes. World J Gastroenterol, 24:4846–61. DOI: 10.3748/wjg.v24.i43.4846.

Zhang W, Xiong Z, Wei T, et al., 2018, Nuclear Factor 90 Promotes Angiogenesis by Regulating HIF-1a/VEGF-A Expression through the PI3K/Akt Signaling Pathway in Human Cervical Cancer. Cell Death Dis, 9:1–13. DOI: 10.1038/s41419-018-0334-2.

Azoitei N, Becher A, Steinestel K, et al., 2016, PKM2 Promotes Tumor Angiogenesis by Regulating HIF-1a through NF-kB Activation. Mol Cancer, 15:3.

DOI: 10.1186/s12943-015-0490-2.

Lang SA, Moser C, Gaumann A, et al., 2007, Targeting Heat Shock Protein 90 in Pancreatic Cancer Impairs Insulin-like Growth Factor-I Receptor Signaling, Disrupts an Interleukin-6/signal-transducer and Activator of Transcription 3/hypoxia-inducible Factor-1a Autocrine Loop, and Reduces Orthotopic Tumor Growth. Clin Cancer Res, 13:6459–68. DOI: 10.1158/1078-0432.ccr-07-1104.

Sahraei M, Roy LD, Curry JM, et al., 2012, MUC1 Regulates PDGFA Expression during Pancreatic Cancer Progression. Oncogene, 31:4935–45. DOI: 10.1038/onc.2011.651.

Shan T, Ma J, Ma Q, Guo K, et al., 2013, b2-AR-HIF-1a: A Novel Regulatory Axis for Stress-induced Pancreatic Tumor Growth and Angiogenesis. Curr Mol Med, 13:1023–34. DOI: 10.2174/15665240113139990055

Carlessi R, Chen Y, Rowlands J, et al., 2017, GLP-1 Receptor Signalling Promotes b-Cell Glucose Metabolism via mTOR-dependent HIF-1a Activation. Sci Rep, 7:1–13. DOI: 10.1038/s41598-017-02838-2.

Li W, Liu H, Qian W, et al., 2018, Hyperglycemia Aggravates Microenvironment Hypoxia and Promotes the Metastatic Ability of Pancreatic Cancer. Comput Struct Biotechnol J, 16:479–87. DOI: 10.1016/j.csbj.2018.10.006.

Zhu S, Deng S, He C, et al., 2018, Reciprocal Loop of Hypoxia‐inducible Factor‐1a (HIF‐1a) and Metastasis‐Associated Protein 2 (MTA2) Contributes to the Progression of Pancreatic Carcinoma by Suppressing E‐cadherin Transcription. J Pathol, 245:349–60. DOI: 10.1002/path.5089.

Kourtidis A, Lu R, Pence LJ, et al., 2017, A Central Role for Cadherin Signaling in Cancer. Exp Cell Res, 358:78–85. DOI: 10.1016/j.yexcr.2017.04.006.

Chen S, Chen JZ, Zhang JQ, et al., 2016, Hypoxia Induces TWIST-activated Epithelial-Mesenchymal Transition and Proliferation of Pancreatic Cancer Cells In Vitro and in Nude Mice. Cancer Lett, 383:73–84. DOI: 10.1016/j.canlet.2016.09.027.

Deng SJ, Chen HY, Ye Z, et al., 2018, Hypoxia-induced LncRNA-BX111 Promotes Metastasis and Progression of Pancreatic Cancer through Regulating ZEB1 Transcription. Oncogene, 37:5811–28. DOI: 10.1038/s41388-018-0382-1.

Lu Y, Ji N, Wei W, et al, 2017, MiR-142 Modulates Human Pancreatic Cancer Proliferation and Invasion by Targeting Hypoxia-Inducible Factor 1 (HIF-1a) in the Tumor Microenvironments. Biol Open, 6:252–9. DOI: 10.1242/bio.021774.

Zhang Q, Lou Y, Zhang J, et al., 2017, Hypoxia-inducible Factor-2a Promotes Tumor Progression and has Crosstalk with Wnt/b-catenin Signaling in Pancreatic Cancer. Mol Cancer, 16:119. DOI: 10.1186/s12943-017-0689-5.